{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:12:54Z","timestamp":1783739574650,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejso.2025.111316","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T16:12:28Z","timestamp":1764691948000},"page":"111316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The overarching prognostic role of tumor progression prior to cytoreductive hepatectomy in NETLM"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9684-8918","authenticated-orcid":false,"given":"Vanja","family":"Podrascanin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0448-0588","authenticated-orcid":false,"given":"Markus","family":"Ammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hallbera","family":"Gudmundsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-1228","authenticated-orcid":false,"given":"Yawen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Santol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3654-8601","authenticated-orcid":false,"given":"Cornelius A.","family":"Thiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne G.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Truty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7960-3254","authenticated-orcid":false,"given":"Michael L.","family":"Kendrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory L.","family":"Smoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8275-126X","authenticated-orcid":false,"given":"Jeff L.","family":"Fidler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8460-1257","authenticated-orcid":false,"given":"Thorvardur R.","family":"Halfdanarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4666-5337","authenticated-orcid":false,"given":"Patrick P.","family":"Starlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2025.111316_bib1","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201cCarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2025.111316_bib2","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1200\/JCO.2010.33.0688","article-title":"Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression","volume":"29","author":"Panzuto","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2025.111316_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.15798","article-title":"Epidemiology of neuroendocrine neoplasms in the US","volume":"8","author":"Dasari","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejso.2025.111316_bib4","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1245\/s10434-023-13372-z","article-title":"Survival and symptomatic relief after cytoreductive hepatectomy for neuroendocrine tumor liver metastases: long-term Follow-up evaluation of more than 500 patients","volume":"30","author":"Gudmundsdottir","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2025.111316_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1072-7515(03)00230-8","article-title":"Surgical treatment of neuroendocrine metastases to the liver: : a plea for resection to increase survival","volume":"197","author":"Sarmiento","year":"2003","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ejso.2025.111316_bib6","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.surg.2015.03.033","article-title":"Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: a Markov decision model","volume":"158","author":"Spolverato","year":"2015","journal-title":"Surgery"},{"key":"10.1016\/j.ejso.2025.111316_bib7","doi-asserted-by":"crossref","first-page":"e1082","DOI":"10.1634\/theoncologist.2018-0672","article-title":"Value of Tumor Growth Rate (TGR) as an early biomarker predictor of patients' outcome in neuroendocrine tumors (NET)\u2014The GREPONET Study","volume":"24","author":"Lamarca","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ejso.2025.111316_bib8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"Recist 1.1\u2014Update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2025.111316_bib9","first-page":"205","volume":"vol. 92","author":"Therasse","year":"2000"},{"key":"10.1016\/j.ejso.2025.111316_bib10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.ejso.2025.111316_bib11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/oncolo\/oyac049","article-title":"Survival and incidence patterns of pancreatic neuroendocrine tumors over the last 2 decades: a SEER database analysis","volume":"27","author":"Sonbol","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.ejso.2025.111316_bib12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00534-005-0999-7","article-title":"Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system","volume":"12","author":"Strasberg","year":"2005","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"10.1016\/j.ejso.2025.111316_bib13","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/MPA.0000000000000846","article-title":"The surgical management of small bowel neuroendocrine tumors: Consensus guidelines of the north American neuroendocrine tumor society","volume":"46","author":"Howe","year":"2017","journal-title":"Pancreas"},{"key":"10.1016\/j.ejso.2025.111316_bib14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2025.111316_bib15","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.surg.2010.10.001","article-title":"Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS)","volume":"149","author":"Rahbari","year":"2011","journal-title":"Surgery"},{"key":"10.1016\/j.ejso.2025.111316_bib16","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1477-2574.2011.00319.x","article-title":"Post-hepatectomy haemorrhage: a definition and grading by the International Study Group of Liver Surgery (ISGLS)","volume":"13","author":"Rahbari","year":"2011","journal-title":"HPB"},{"key":"10.1016\/j.ejso.2025.111316_bib17","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.surg.2010.12.002","article-title":"Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery","volume":"149","author":"Koch","year":"2011","journal-title":"Surgery"},{"key":"10.1016\/j.ejso.2025.111316_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejso.2025.111316_bib19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","article-title":"Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?","volume":"23","author":"Das","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ejso.2025.111316_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.24750","article-title":"Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States","volume":"4","author":"Xu","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejso.2025.111316_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0290","article-title":"Association of upfront peptide receptor radionuclide therapy with progression-free survival among patients with enteropancreatic neuroendocrine tumors","volume":"5","author":"Pusceddu","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejso.2025.111316_bib22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/modpathol.2008.177","article-title":"Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors","volume":"22","author":"Couvelard","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ejso.2025.111316_bib23","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/PAS.0b013e31821a0696","article-title":"Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification","volume":"35","author":"Yang","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejso.2025.111316_bib24","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1159\/000510445","article-title":"Tumor growth rate to predict the outcome of patients with neuroendocrine tumors: performance and sources of variability","volume":"111","author":"Dromain","year":"2021","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ejso.2025.111316_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13311","article-title":"Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: alternatives to RECIST","volume":"35","author":"De Mestier","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.ejso.2025.111316_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2023.101827","article-title":"Appropriate use of morphological imaging for assessing treatment response and disease progression of neuroendocrine tumors","volume":"37","author":"Ronot","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.ejso.2025.111316_bib27","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1210\/jc.2011-0666","article-title":"Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus","volume":"96","author":"Yao","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejso.2025.111316_bib28","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/jso.26285","article-title":"Duodenal, ampullary, and pancreatic neuroendocrine tumors: oncologic outcomes are driven by tumor biology and tissue of origin","volume":"123","author":"Schmocker","year":"2021","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejso.2025.111316_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13000","article-title":"Prognostic features of gastro\u2010entero\u2010pancreatic neuroendocrine neoplasms in primary and metastatic sites: grade, mesenteric tumour deposits and emerging novelties","volume":"33","author":"Kankava","year":"2021","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.ejso.2025.111316_bib30","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000039616","article-title":"Incidence, survival, and prognostic nomogram of patients with small intestinal neuroendocrine tumors: a SEER population-based study","volume":"103","author":"Peng","year":"2024","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.ejso.2025.111316_bib31","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.pan.2019.09.015","article-title":"Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: a comparison between pancreatic and gastrointestinal localizations","volume":"19","author":"Panzuto","year":"2019","journal-title":"Pancreatology"},{"key":"10.1016\/j.ejso.2025.111316_bib32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00428-010-0924-6","article-title":"The ENETS and AJCC\/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement","volume":"456","author":"Kl\u00f6ppel","year":"2010","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ejso.2025.111316_bib33","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11605-016-3228-6","article-title":"A novel nomogram to predict the prognosis of patients undergoing liver resection for neuroendocrine liver metastasis: an analysis of the Italian neuroendocrine liver metastasis database","volume":"21","author":"Ruzzenente","year":"2017","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.ejso.2025.111316_bib34","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znae178","article-title":"Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): Multicentre phase II study","volume":"111","author":"Partelli","year":"2024","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2025.111316_bib35","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2025.111316_bib36","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS515","article-title":"Randomized phase II trial of postoperative adjuvant capecitabine and temozolomide versus observation in high-risk pancreatic neuroendocrine tumors: SWOG S2104","volume":"40","author":"Soares","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325017445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325017445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T02:27:11Z","timestamp":1783736831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798325017445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0748798325017445"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2025.111316","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The overarching prognostic role of tumor progression prior to cytoreductive hepatectomy in NETLM","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2025.111316","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111316"}}